Agilent Technologies, Inc. $A Shares Sold by The Manufacturers Life Insurance Company

Key Points

• The Manufacturers Life Insurance Company has reduced its stake in Agilent Technologies by 19.4%, now holding approximately 0.06% of the company, valued at about $19.78 million.
• Agilent Technologies reported $1.74 billion in quarterly revenue, surpassing analysts' expectations, with a year-over-year revenue growth of 10.1%.
• Analysts have mixed ratings for Agilent Technologies, with six rating it as a "Buy" and six as "Hold," and an average target price of $139.25.

The Manufacturers Life Insurance Company lessened its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 19.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 169,061 shares of the medical research company's stock after selling 40,765 shares during the quarter. The Manufacturers Life Insurance Company owned 0.06% of Agilent Technologies worth $19,777,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in A. GAMMA Investing LLC lifted its holdings in shares of Agilent Technologies by 15,648.1% in the 1st quarter. GAMMA Investing LLC now owns 627,247 shares of the medical research company's stock worth $73,375,000 after acquiring an additional 623,264 shares during the last quarter. Two Sigma Investments LP lifted its holdings in shares of Agilent Technologies by 345.9% in the 4th quarter. Two Sigma Investments LP now owns 769,897 shares of the medical research company's stock worth $103,428,000 after acquiring an additional 597,249 shares during the last quarter. Iron Triangle Partners LP bought a new stake in shares of Agilent Technologies in the 4th quarter worth about $80,110,000. Mackenzie Financial Corp lifted its holdings in shares of Agilent Technologies by 141.5% in the 1st quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company's stock worth $109,481,000 after acquiring an additional 548,344 shares during the last quarter. Finally, Parnassus Investments LLC lifted its holdings in shares of Agilent Technologies by 38.3% in the 1st quarter. Parnassus Investments LLC now owns 1,577,999 shares of the medical research company's stock worth $184,594,000 after acquiring an additional 437,242 shares during the last quarter. Institutional investors own 87.41% of the company's stock.

Agilent Technologies Stock Performance

NYSE:A traded up $0.21 during trading hours on Friday, hitting $128.69. 1,633,203 shares of the company were exchanged, compared to its average volume of 1,522,644. The stock has a market capitalization of $36.48 billion, a price-to-earnings ratio of 30.21, a PEG ratio of 4.00 and a beta of 1.24. Agilent Technologies, Inc. has a 52-week low of $96.43 and a 52-week high of $153.84. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. The company's 50 day moving average price is $119.22 and its 200-day moving average price is $116.19.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.67 billion. During the same period in the previous year, the business posted $1.32 EPS. The business's quarterly revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, research analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on A. Barclays reiterated an "equal weight" rating and set a $125.00 price objective on shares of Agilent Technologies in a report on Friday, August 29th. Evercore ISI decreased their price objective on shares of Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating for the company in a report on Thursday, August 28th. Wells Fargo & Company lifted their price objective on shares of Agilent Technologies from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Thursday, August 28th. Robert W. Baird lifted their price objective on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday, August 28th. Finally, UBS Group cut their target price on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a research report on Thursday, May 29th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $139.25.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the sale, the chief executive officer directly owned 37,448 shares in the company, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.26% of the company's stock.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.